Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting

Luigi Celio, Chiara Fabbroni

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Prevention of nausea and vomiting is of paramount importance for ensuring that patients undergoing anticancer treatments have optimal quality of life. The oral fixed-dose combination of netupitant/palonosetron (NEPA) was developed to improve dual-targeted anti-emetic prophylaxis administration. Areas covered: This article summarizes the available evidence for the pharmacology, safety, and efficacy of the new intravenous formulation of NEPA (IV NEPA). The clinical role of NEPA and future perspectives for anti-emetic research are also discussed. Expert opinion: Each patient undergoing emetogenic anticancer treatments should receive guideline-consistent prophylaxis from the beginning of therapy. However, physicians may be nonadherent to guidelines in prescribing prophylaxis, while patients may be nonadherent in taking their medication as prescribed. Therefore, simplification of anti-emetic regimens with agents that are administered once per treatment cycle may contribute to improve guideline adherence by physicians and compliance with regimens by patients. IV NEPA may also help overcome potential logistical issues surrounding the oral administration of NEPA. While short-term olanzapine can improve control of nausea, it also causes transient but significantly increased sedation. This side effect as well as new evidence support further efforts to explore the overall potential of NEPA against nausea caused by either chemotherapy or concurrent chemo-radiotherapy.

Original languageEnglish
Pages (from-to)1267-1277
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number11
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Radio
Nausea
Vomiting
Antiemetics
Drug Therapy
olanzapine
Guidelines
Physicians
Guideline Adherence
Therapeutics
Expert Testimony
Oral Administration
Radiotherapy
Quality of Life
netupitant
palonosetron
Pharmacology
Safety
Research

Keywords

  • Administration, Intravenous
  • Antiemetics/pharmacology
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Humans
  • Isoquinolines/pharmacology
  • Nausea/chemically induced
  • Palonosetron
  • Pyridines/pharmacology
  • Quinuclidines/pharmacology
  • Radiotherapy/adverse effects
  • Vomiting/chemically induced

Cite this

Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting. / Celio, Luigi; Fabbroni, Chiara.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 11, 08.2018, p. 1267-1277.

Research output: Contribution to journalArticle

@article{023d988fe1fb40a492c5355b815a8b43,
title = "Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting",
abstract = "INTRODUCTION: Prevention of nausea and vomiting is of paramount importance for ensuring that patients undergoing anticancer treatments have optimal quality of life. The oral fixed-dose combination of netupitant/palonosetron (NEPA) was developed to improve dual-targeted anti-emetic prophylaxis administration. Areas covered: This article summarizes the available evidence for the pharmacology, safety, and efficacy of the new intravenous formulation of NEPA (IV NEPA). The clinical role of NEPA and future perspectives for anti-emetic research are also discussed. Expert opinion: Each patient undergoing emetogenic anticancer treatments should receive guideline-consistent prophylaxis from the beginning of therapy. However, physicians may be nonadherent to guidelines in prescribing prophylaxis, while patients may be nonadherent in taking their medication as prescribed. Therefore, simplification of anti-emetic regimens with agents that are administered once per treatment cycle may contribute to improve guideline adherence by physicians and compliance with regimens by patients. IV NEPA may also help overcome potential logistical issues surrounding the oral administration of NEPA. While short-term olanzapine can improve control of nausea, it also causes transient but significantly increased sedation. This side effect as well as new evidence support further efforts to explore the overall potential of NEPA against nausea caused by either chemotherapy or concurrent chemo-radiotherapy.",
keywords = "Administration, Intravenous, Antiemetics/pharmacology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Humans, Isoquinolines/pharmacology, Nausea/chemically induced, Palonosetron, Pyridines/pharmacology, Quinuclidines/pharmacology, Radiotherapy/adverse effects, Vomiting/chemically induced",
author = "Luigi Celio and Chiara Fabbroni",
year = "2018",
month = "8",
doi = "10.1080/14656566.2018.1494726",
language = "English",
volume = "19",
pages = "1267--1277",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting

AU - Celio, Luigi

AU - Fabbroni, Chiara

PY - 2018/8

Y1 - 2018/8

N2 - INTRODUCTION: Prevention of nausea and vomiting is of paramount importance for ensuring that patients undergoing anticancer treatments have optimal quality of life. The oral fixed-dose combination of netupitant/palonosetron (NEPA) was developed to improve dual-targeted anti-emetic prophylaxis administration. Areas covered: This article summarizes the available evidence for the pharmacology, safety, and efficacy of the new intravenous formulation of NEPA (IV NEPA). The clinical role of NEPA and future perspectives for anti-emetic research are also discussed. Expert opinion: Each patient undergoing emetogenic anticancer treatments should receive guideline-consistent prophylaxis from the beginning of therapy. However, physicians may be nonadherent to guidelines in prescribing prophylaxis, while patients may be nonadherent in taking their medication as prescribed. Therefore, simplification of anti-emetic regimens with agents that are administered once per treatment cycle may contribute to improve guideline adherence by physicians and compliance with regimens by patients. IV NEPA may also help overcome potential logistical issues surrounding the oral administration of NEPA. While short-term olanzapine can improve control of nausea, it also causes transient but significantly increased sedation. This side effect as well as new evidence support further efforts to explore the overall potential of NEPA against nausea caused by either chemotherapy or concurrent chemo-radiotherapy.

AB - INTRODUCTION: Prevention of nausea and vomiting is of paramount importance for ensuring that patients undergoing anticancer treatments have optimal quality of life. The oral fixed-dose combination of netupitant/palonosetron (NEPA) was developed to improve dual-targeted anti-emetic prophylaxis administration. Areas covered: This article summarizes the available evidence for the pharmacology, safety, and efficacy of the new intravenous formulation of NEPA (IV NEPA). The clinical role of NEPA and future perspectives for anti-emetic research are also discussed. Expert opinion: Each patient undergoing emetogenic anticancer treatments should receive guideline-consistent prophylaxis from the beginning of therapy. However, physicians may be nonadherent to guidelines in prescribing prophylaxis, while patients may be nonadherent in taking their medication as prescribed. Therefore, simplification of anti-emetic regimens with agents that are administered once per treatment cycle may contribute to improve guideline adherence by physicians and compliance with regimens by patients. IV NEPA may also help overcome potential logistical issues surrounding the oral administration of NEPA. While short-term olanzapine can improve control of nausea, it also causes transient but significantly increased sedation. This side effect as well as new evidence support further efforts to explore the overall potential of NEPA against nausea caused by either chemotherapy or concurrent chemo-radiotherapy.

KW - Administration, Intravenous

KW - Antiemetics/pharmacology

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Humans

KW - Isoquinolines/pharmacology

KW - Nausea/chemically induced

KW - Palonosetron

KW - Pyridines/pharmacology

KW - Quinuclidines/pharmacology

KW - Radiotherapy/adverse effects

KW - Vomiting/chemically induced

U2 - 10.1080/14656566.2018.1494726

DO - 10.1080/14656566.2018.1494726

M3 - Article

C2 - 29985663

VL - 19

SP - 1267

EP - 1277

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 11

ER -